Condition

Acute Leukemia (2)

Chronic Myelogenous Leukemia (CML) (2)

Lymphoma (2)

Acute Lymphoblastic Leukemia (ALL) (1)

Acute Myelogenous Leukemia (AML) (1)

Hematological Malignancies (1)

Myelodysplasia (1)

Myelodysplastic Syndrome (MDS) (1)

Overall Status

Active, not recruiting (2)

Phase

phase 3 (2)

Sponsor

Gamida Cell ltd (1)

Medical College of Wisconsin (1)

Collaborator

Blood and Marrow Transplant Clinical Trials Network (1)

National Cancer Institute (NCI) (1)

National Heart, Lung, and Blood Institute (NHLBI) (1)

National Marrow Donor Program (1)

Intervention

cord blood unit (1)

cyclophosphamide (1)

methotrexate (1)

mobilized peripheral blood stem cell graft with tacrolimus/methotrexate (1)

mobilized peripheral blood stem cell graft with tacrolimus/mycophenolate mofetil/post-transplant cyclophosphamide (1)

mycophenolate mofetil (1)

nicord® (omidubicel) (1)

tacrolimus (1)

Study Documents

Intervention Type

drug (2)

other (1)

procedure (1)

Funder Type

Industry (1)

Other (1)

Study Type

Interventional (2)

chronic myelogenous leukemia (cml)

Showing NaN - NaN of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplasia Trial in United States (Mobilized Peripheral Blood Stem Cell

Active, not recruiting

Acute Leukemia
+3 more

Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate
+5 more

Birmingham, Alabama
+38 more

Oct 25, 2021

Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML) Trial in Worldwide (NiCord®

Active, not recruiting

Hematological Malignancies
+6 more

NiCord® (omidubicel)
Cord Blood Unit

Los Angeles, California
+51 more

Jan 7, 2021